FIELD: medicine, ophthalmology.
SUBSTANCE: at the background of anti-tuberculosis therapy one should additionally introduce Betaleukin parabulbarly per 0.33 ng every other day, therapy course - 5 procedures. The innovation provides local immunostimulating action of Betaleukin.
EFFECT: higher efficiency of therapy.
1 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATMENT OF TUBERCULOSIS UVEITIS | 2004 |
|
RU2290191C2 |
| REGENERATING RESOLVENT AND WAYS OF TREATMENT BY MEANS OF THIS AGENT | 2007 |
|
RU2362554C2 |
| METHOD FOR PREDICTING TUBERCULOUS UVEITIS THERAPY IN PATIENTS OF DIFFERENT AGE GROUPS | 2005 |
|
RU2294149C1 |
| METHOD FOR TREATING TUBERCULOUS UVEITES | 2006 |
|
RU2318534C2 |
| METHOD OF REGISTERING APPEARANCE OF FOCAL RESPONSE IN CASE OF CHORIORETINITIS | 2011 |
|
RU2455935C1 |
| METHOD FOR PREDICTING TUBERCULOSIS ETIOLOGY OF CHORIORETINITIS | 2005 |
|
RU2297186C1 |
| METHOD OF TREATING CHORIORETINAL DYSTROPHIES AFTER TUBERCULOSIS CHORIORETINITIS | 2009 |
|
RU2463998C2 |
| METHOD FOR DIAGNOSING ACTIVE TUBERCULOSIS UVEITIS | 1994 |
|
RU2121688C1 |
| METHOD FOR TREATING PULMONARY TUBERCULOSIS AT PREDOMINANTLY PRODUCTIVE TYPE OF TISSUE REACTION | 2000 |
|
RU2204409C2 |
| METHOD FOR DIAGNOSING EYE FUNDUS DISEASES | 2005 |
|
RU2316994C2 |
